• RNA Subpopulations Targeted for Control of Cardiovascular Disease

    Several non-coding RNA subpopulations show promise as therapeutic targets in the control of cardiovascular disease, according to Stefanie Dimmeler, who delivered the Louis B. Jaques Plenary Lecture at the ISTH 2015 Congress Thursday.
    A small number of phase II trials in this area have been completed, with more clinical trials anticipated. The real excitement about non-coding …

  • Meaningful Genetic Testing for Thrombophilia is Tantalizingly Close

    Multiple strategies for examining genetic determinants of thrombosis are likely to explain clotting events mediated by a complex set of interactions that includes multiple genes and environmental factors, according to David Ginsburg, who delivered Wednesday’s Michael E. Nesheim Plenary Lecture.
    This progress is important, he said, because none of the genes associated with blood clotting disorders …

  • Why We Miss the Mark on Preventing Cardiovascular Disease

    If you don’t think clinicians should be worried about the current state of cardiovascular disease (CVD) prevention, consider data from the 2011 World Health Organization Global Atlas on CVD Prevention and Control. It found that worldwide, CVD accounts for 31% of deaths: 17.5 million in 2012, projected to increase to 23.3 million in 2030.
    At the …

  • Advances in Imaging are Helping Researchers Better Understand Immunity

    For more than two decades, Paul Kubes has been studying ways to directly visualize the role of immune cells during inflammation, infection and tissue injury, both in vitro and in vivo.
    During the Tuesday morning J. Fraser Mustard Plenary Lecture at the ISTH 2015 Congress, he discussed several examples of how cutting-edge technologies, such as spinning-disk …

  • Leader in Cardiovascular Medicine Thanks ISTH in Schofield Plenary Lecture

    In the Frank Schofield Plenary Lecture on Monday morning, Eugene Braunwald, Brigham and Women’s Hospital, Harvard Medical School, Boston, first thanked the members of ISTH for what they have achieved so far in controlling thrombosis and then asked for more.
    “We want you to give us greater improvement in the efficacy-bleeding relationship,” Braunwald said at the …